The Effect of Arginine as an Anti-Aggregation Excipient on Recombinant Human Growth Hormone
Trends in Peptide and Protein Sciences,
Vol. 1 No. 1 (2016),
4 October 2016
,
Page 31-37
https://doi.org/10.22037/tpps.v1i1.13040
Abstract
Aggregation is one of the main physical instabilities of proteins, which might occur during all steps of the manufacturing and storage of products. The presence of protein aggregates may result in the reduction of activity, induce immunologic responses and failure of therapeutic efficiency. Therefore, using additives in drug formulations is one of the essential approaches to prevent protein aggregation. The main objective of this study was to evaluate the inhibitory influence of arginine or glycine as excipients on the aggregation behavior of recombinant human growth hormone (rhGH). Two types of mechanical and thermal stresses including freeze-thaw and vortex-agitation were applied to the 1 mg/mL protein solution in PBS buffer (25 mM, pH = 7) in the presence and absence of arginine and glycine. The influence of arginine or glycine at the concentration of 320 mM on reduction of rhGH thermal/mechanical-induced aggregation was evaluated using SE-HPLC and turbidity measurement. The results of this study revealed that the monomer concentration decreased linearly; and therefore, aggregate formation was intensified with the increase in the number of freeze-thaw cycles. Moreover, it was found that a significant amount of rhGH (> 80%) was rapidly adsorbed at the walls of the vessels or converted to insoluble aggregates. Arginine decreased the insoluble aggregate formed during the freeze-thaw cycling more effectively than glycine. In addition, following the vortex-agitation stress, arginine had the optimum preventive effect in aggregate formation in contrast to glycine, which increased the formation of insoluble aggregates. The findings revealed that arginine may be a potential additive in preserving rhGH against thermal/mechanical-induced aggregation.
Highlights
- Aggregation is one of the main physical instabilities of proteins.
- Protein aggregation may result in a compromise of safety and efficacy of biopharmaceutical products.
- Arginine at the concentration of 320 mM reduced rhGH thermal/mechanical-induced aggregation.
- Arginine, in contrast to glycine, optimally decreased the formation of insoluble aggregates.
- Aggregation
- Arginine
- Glycine
- Protein stability
- Recombinant human growth hormone.
How to Cite
References
Arakawa, T., D. Ejima, K. Tsumoto, N. Obeyama, Y. Tanaka, Y. Kita and S. N. Timasheff, (2007). "Suppression of protein interactions by arginine: a proposed mechanism of the arginine effects." Biophysical Chemistry. 127(1): 1-8.
Arakawa, T. and S. Timasheff, (1985). "The stabilization of proteins by osmolytes." Biophysical Journal. 47(3): 411.
Arakawa, T. and S. N. Timasheff, (1983). "Preferential interactions of proteins with solvent components in aqueous amino acid solutions."Archives of Biochemistry and Biophysics. 224(1): 169-177.
Arakawa, T., K. Tsumoto, K. Nagase and D. Ejima, (2007). "The effects of arginine on protein binding and elution in hydrophobic interaction and ion-exchange chromatography." Protein Expression and Purification. 54(1): 110-116.
Bajorunaite, E., J. Sereikaite and V.-A. Bumelis, (2007). "L-Arginine suppresses aggregation of recombinant growth hormones in refolding process from E. coli inclusion bodies." The Protein Journal. 26(8): 547- 555.
Bhatnagar, B. S., R. H. Bogner and M. J. Pikal, (2007). "Protein stability during freezing: separation of stresses and mechanisms of protein stabilization." Pharmaceutical Development and Technology. 12(5): 505- 523.
Bidlingmaier, M. and C. J. Strasburger, (2010). Growth hormone. In: Doping in Sports: Biochemical Principles, Effects and Analysis, D. Thieme & P. Hemmersbach (ed), Handbook of Experimental Pharmacology (vol. 195). Springer. Berlin. 187-200.
Cázares-Delgadillo, J., A. Ganem-Rondero and Y. N. Kalia, (2011). "Human growth hormone: New delivery systems, alternative routes of administration, and their pharmacological relevance." European Journal of Pharmaceutics and Biopharmaceutics. 78(2): 278-288.
Den Engelsman, J., P. Garidel, R. Smulders, H. Koll, B. Smith, S. Bassarab, A. Seidl, O. Hainzl and W. Jiskoot, (2011). "Strategies for the assessment of protein aggregates in pharmaceutical biotech product development." Pharmaceutical Research. 28(4): 920-933.
Fradkin, A. H., J. F. Carpenter and T. W. Randolph, (2009). "Immunogenicity of aggregates of recombinant human growth hormone in mouse models." Journal of Pharmaceutical Sciences. 98(9): 3247-3264.
Kim, M.-J., H. S. Park, K. H. Seo, H.-J. Yang, S.-K. Kim and J.-H. Choi, (2013). "Complete solubilization and purification of recombinant human growth hormone produced in Escherichia coli." PloS One. 8(2): e56168.
Maggio, E. (2010). "Use of excipients to control aggregation in peptide and protein formulations." Journal of Excipients and Food Chemicals. 1(2): 40-49.
Mahler, H. C., W. Friess, U. Grauschopf and S. Kiese, (2009). "Protein aggregation: pathways, induction factors and analysis." Journal of Pharmaceutical Sciences. 98(9): 2909-2934.
Moore, W. V. and P. Leppert, (1980). "Role of aggregated human growth hormone (hGH) in development of antibodies to hGH." The Journal of Clinical Endocrinology & Metabolism. 51(4): 691-697.
Mulinacci, F., M. AH Capelle, R. Gurny, A. F Drake and T. Arvinte, (2011). "Stability of human growth hormone: influence of methionine oxidation on thermal folding." Journal of Pharmaceutical Sciences. 100(2): 451-463.
Narhi, L. O., J. Schmit, K. Bechtold-Peters and D. Sharma, (2012). "Classification of protein aggregates." Journal of Pharmaceutical Sciences, 101(2): 493-498.
Gohil, K. (2015). "Long-Acting Therapies Will Expand Growth Hormone Deficiency Market." Pharmacy and Therapeutics. 40(11): 772.
Philo, J. S. and T. Arakawa, (2009). "Mechanisms of protein aggregation." Current Pharmaceutical Biotechnology, 10(4): 348-351.
Singh, L. R., N. K. Poddar, T. A. Dar, R. Kumar and F. Ahmad, (2011). "Protein and DNA destabilization by osmolytes: the other side of the coin." Life Science. 88(3-4): 117-125.
Tsumoto, K., D. Ejima, Y. Kita and T. Arakawa, (2005). "Review: Why is arginine effective in suppressing aggregation?" Protein and Peptide Letters. 12(7): 613-619.
Wilhelmsen, T. W., V. Skibeli and F. C. Arntzen, (2010). "Stability study of somatropin by capillary zone electrophoresis." Procedia Chemistry. 2(1): 34-45.
- Abstract Viewed: 1792 times
- PDF Downloaded: 432 times